2023
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma
Ernst M, Navani V, Wells J, Donskov F, Basappa N, Labaki C, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Parnis F, Suarez C, Yuasa T, Lalani A, Alva A, Bjarnason G, Choueiri T, Heng D. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. European Urology 2023, 84: 109-116. PMID: 36707357, DOI: 10.1016/j.eururo.2023.01.001.Peer-Reviewed Original ResearchConceptsInternational mRCC Database ConsortiumMetastatic renal cell carcinomaInternational mRCC Database Consortium risk groupIO combination therapyIpi-nivoOverall survivalRenal cell carcinomaCombination therapyTreatment durationRisk groupsCell carcinomaImmuno-oncologyTreatment cohortsInternational Metastatic Renal Cell Carcinoma Database Consortium modelStandard of care first-line treatmentVascular endothelial growth factor-targeted therapyFirst-line combination therapyMedian follow-up timePoor-risk groupEndpoint of OSFirst-line treatmentKaplan-Meier methodLog-rank testModel stratified patientsShort follow-up
2022
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
Ernst M, Navani V, Wells J, Donskov F, Basappa N, Labaki C, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Parnis F, Suárez C, Yuasa T, Kapoor A, Alva A, Bjarnason G, Choueiri T, Heng D. Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 308-308. DOI: 10.1200/jco.2022.40.6_suppl.308.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaVascular endothelial growth factor-targeted therapyIpi-nivoImmuno-oncology agentsOverall survivalCombination therapyComplete responseFirst-lineFirst-line treatment of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaInternational mRCC Database Consortium criteriaClinical trialsFirst-line combination therapyEfficacy of combination therapyNon-clear cell histologyTherapy to deathFirst-line treatmentLog-rank testRenal cell carcinomaReal-world survivalCell histologySarcomatoid featuresOS outcomesLiver metastasesPredictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
Navani V, Ernst M, Wells C, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Weickhardt A, Suárez C, Kapoor A, Lee J, Choueiri T, Heng D. Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 310-310. DOI: 10.1200/jco.2022.40.6_suppl.310.Peer-Reviewed Original ResearchAssociated with responseCytoreductive nephrectomyIpi-nivoLung metastasesMetastatic renal cell carcinomaPresence of lung metastasesResponse to first-lineImmunotherapy combination regimensMedian overall survivalRenal cell carcinomaPredictors of responseEndothelial growth factorIpilimumab-nivolumabSarcomatoid histologyRECIST v1.1Combination regimensOverall survivalCombination therapyCell carcinomaFirst-lineResponse of CRNon-respondersPrognostic riskClinical variablesPatient counseling
2021
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Gan C, Wells J, Schmidt A, Powles T, Tran B, Meza L, Labaki C, Lee J, Wood L, Shapiro J, Ernst D, Kapoor A, Canil C, Yuasa T, McKay R, Beuselinck B, Donskov F, Dudani S, Choueiri T, Heng D. Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal Of Clinical Oncology 2021, 39: 4554-4554. DOI: 10.1200/jco.2021.39.15_suppl.4554.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaIpi-nivoOverall survivalCell histologyInternational mRCC Database Consortium criteriaOutcomes of first-lineTreatment durationNon-clear cell histologyPoor-risk diseaseTyrosine kinase inhibitorsRenal cell carcinomaRisk categoriesMedian OSBrain metastasesBone metastasesLiver metastasesPoor riskRisk diseaseCell carcinomaFirst-lineMedian ageProgressive diseaseMedian TDNeutrophil count